A phase II, double-blinded, placebo-controlled, clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder.
Not yet recruitingCTIS2024-510873-11-00
Apurano Pharmaceuticals GmbHBorderline personality disorder
Target: 154Updated: 2026-04-28